Impressive results from two efficacy trials of a long-acting form of the integrase inhibitor cabotegravir (CAB LA) have boosted prospects for long-acting HIV pre-exposure prophylaxis (PrEP). In both cases, CAB LA proved superior to oral Truvada PrEP (see table below).
A position paper of the BEAT-HIV Collaboratory
The pandemic is hitting Latinx people harder; HIV researchers say it’s time to create policy changes
An update on research for prevention, treatment, and cure using broadly neutralizing antibodies
Pregnancy and dolutegravir; AIDS Quilt finds a new home; survey on women living with HIV; and more
Current and new strategies to achieve HBV and HIV cure, and synergies between the two fields.
Biktarvy and antacids. Descovy FDA hearing. Updated guidelines for transgender individuals. Biktarvy and kids. PrEP4Love. Michael Johnson freed.
A behind-the-scenes look at a planned clinical trial of treatment interruption with new weapons aimed at remission—a stepping stone toward a cure.
HIV cure scientific highlights from the 2017 HIV Persistence Meeting
The co-creator and star of the web series Merce envisions life with an HIV cure
Modifying immune system cells to resist, attack, or remove HIV altogether
Anti-alcohol drug, gay journalist grant, life insurance for people with HIV, Grindr & PrEP